Monitor the outcome of the say-on-pay vote and the auditor ratification — a low say-on-pay approval or significant withhold votes on directors could signal governance concerns. The auditor change from Baker Tilly to EY is clean but warrants watching for any future restatements or control issues. Montanova's 43.48% stake and board representation give it effective control over all shareholder votes.
Price Chart
Executive Summary
Benitec Biopharma filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held on December 3, 2026. The filing covers the election of three Class I directors (Sharon Mates, Kishen Mehta, Edward Smith), ratification of Ernst & Young as the new independent auditor (replacing Baker Tilly), and a non-binding say-on-pay vote on executive compensation. The proxy also discloses that Montanova Capital (formerly Suvretta Capital) holds a 43.48% controlling stake, and that the company raised approximately $104.5 million in gross proceeds from a November 2025 offering and $30.5 million from a March 2025 offering, with Montanova participating in both.
Key Facts
- Annual Meeting scheduled for December 3, 2026, held virtually; record date October 13, 2026 with 34,889,313 shares outstanding.
- Montanova Capital LLC (formerly Suvretta Capital) is the largest stockholder at 43.48% beneficial ownership; two Montanova employees (Kishen Mehta, David Friedman) serve on the board.
- Auditor changed: Baker Tilly dismissed September 18, 2026; Ernst & Young engaged for FY ending June 30, 2027 — no disagreements or reportable events except a remediated material weakness.
- CEO Jerel Banks total compensation for FY2026: $6,516,319 (salary $667,000, bonus $550,275, option awards $5,252,400).
- Net loss widened to $45.67 million in FY2026 from $37.86 million in FY2025; cumulative TSR of $330.18 on a $100 investment since June 30, 2023.
- November 2025 offering raised ~$104.5M gross proceeds; March 2025 offering raised ~$30.5M gross proceeds — both included participation by Montanova.
- 14,604,643 pre-funded warrants outstanding as of record date, exercisable at $0.0001 per share, not yet voted.
- Say-on-pay vote is advisory; last year's approval rate not disclosed in this filing.
Financial Impact
No new financial impact from this routine proxy filing. Prior capital raises totaled ~$135M gross proceeds in FY2026.
Risk Factors
- Montanova Capital's 43.48% ownership gives it effective control over all director elections and proposals — minority shareholders have no practical ability to influence outcomes.
- Net loss widened 21% year-over-year to $45.67M; pre-funded warrants representing 14.6M additional shares could cause future dilution upon exercise.
- Auditor change from Baker Tilly to EY, while clean, introduces transition risk in the first year of a new audit relationship.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001193125-26-426733 |
| Document: 0001193125-26-426733-index-headers.html | 0001193125-26-426733 |
| Document: 0001193125-26-426733-index.html | 0001193125-26-426733 |
| Document: 0001193125-26-426733.txt | 0001193125-26-426733 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | DEFA14A | $8.50 $8.82 | ▲ +3.76% | ▲ +4.95% | $8.59 (+1.06%) |
Oct 20, 2026 6d ago | DEF 14A | $8.50 $8.82 | ▲ +3.76% | ▲ +4.95% | $8.59 (+1.06%) |
Oct 5, 2026 21d ago | 8-K | $9.23 $9.00 | ▼ −2.49% | ▼ −3.04% | $8.59 (−6.93%) |
Sep 30, 2026 26d ago | 8-K | $9.58 $8.98 | ▼ −6.26% | ▼ −7.00% | $8.59 (−10.33%) |
Sep 22, 2026 4w ago | EFFECT | $10.95 $9.83 | ▲ +10.23% | ▲ +9.51% | $8.59 (+21.55%) |
Sep 14, 2026 6w ago | Press Release | $11.05 $11.04 | ▼ −0.09% | ▲ +0.35% | $8.59 (−22.26%) |
Jun 11, 2026 19w ago | Institutional Cluster | $11.05 $11.18 | ▲ +1.18% | ▲ +0.64% | $8.59 (−22.26%) |
Jun 11, 2026 19w ago | Institutional Cluster | $11.05 $11.18 | ▲ +1.18% | ▲ +0.64% | $8.59 (−22.26%) |
May 14, 2026 23w ago | 8-K | $11.85 $11.49 | ▼ −3.04% | ▼ −1.81% | $8.59 (−27.51%) |
May 14, 2026 23w ago | Press Release | $11.85 $11.49 | ▼ −3.04% | ▼ −1.81% | $8.59 (−27.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers